Skip to main content
Premium Trial:

Request an Annual Quote

Bioneer Receives CE Mark for Coronavirus Kits, Inks Supply Agreement With Romania

NEW YORK – Bioneer said Thursday it has received CE marking for its AccuPower COVID-19 Real-Time RT-PCR Kit and AccuPower SARS-CoV-2 Real-Time RT-PCR Kit and has signed a $1.9 million agreement to supply its ExiStation molecular diagnostics system and coronavirus detection kits in Romania.

Under the terms of the supply agreement, Bioneer will distribute the ExiStation system and COVID-19 test kits to 20 hospitals selected by the Romanian Ministry of Public Health.

Financial and other terms of the agreement were not disclosed.

The COVID-19 test kits, distributed together, use the company’s Dual-HotStart PCR technology to detect RNA targets from clinical samples with high sensitivity and specificity by eliminating non-specific synthesis and amplification, Daejeon, South Korea-based Bioneer said.

The company's ExiStation performs RNA extraction and real-time PCR. It is equipped with an automated system to enable quick and accurate results and can be expanded and configured according to the size of the laboratory, the number of specimens, and the type of inspection, the firm said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.